- Home
- BDTX vs WHF Comparison
BDTX vs WHF Comparison
Compare BDTX & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDTX | WHF |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 152.5M |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BDTX | WHF |
|---|---|---|
| Price | $1.93 | $7.45 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 7 | 2 |
| Target Price | ★ $9.67 | $7.75 |
| AVG Volume (30 Days) | ★ 479.2K | 62.6K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 13.67% |
| EPS Growth | ★ 130.71 | 31.91 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $16.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $6.07 |
| 52 Week High | $4.94 | $8.97 |
Technical Indicators
Market Signals| Indicator | BDTX | WHF |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 60.42 |
| Support Level | $1.61 | $6.82 |
| Resistance Level | $2.28 | $7.60 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 8.75 | 63.27 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.